Heron Therapeutics | HRTX - Des Atouts





Des Atouts Changement Date
ALKERMES USD 4.26B 1.77B 2026-03
Alnylam Pharmaceuticals USD 5.13B 163.22M 2026-03
Amarin USD 645.76M 25.01M 2026-03
ANI Pharmaceuticals USD 1.42B 18.41M 2026-03
Anika Therapeutics USD 179.39M 10.88M 2026-03
Arrowhead Research USD 2.27B 664.08M 2026-03
Eisai JPY 1.45T 37.11B 2026-03
Emergent BioSolutions USD 1.82B 69.9M 2023-12
GlaxoSmithKline GBP 62.87B 1.75B 2026-03
Heron Therapeutics USD 246.22M 9.66M 2026-03
Insmed USD 2.08B 188.7M 2026-03
Ligand Pharmaceuticals USD 1.53B 28.53M 2026-03
Merck USD 128.68B 8.18B 2026-03
Nektar Therapeutics USD 280.41M 20.94M 2025-12
Neurocrine Biosciences USD 4.91B 274.7M 2026-03
Omeros USD 200.57M 34.59M 2025-06
Pacira USD 1.21B 56.38M 2026-03
Regeneron Pharmaceuticals USD 40.87B 310.1M 2026-03
Roche Holding CHF 100.7B 5.94B 2025-12
Sangamo BioSciences USD 97.56M 11.39M 2025-06
Ultragenyx Pharmaceutical USD 1.3B 236M 2026-03
Veracyte USD 1.44B 30.38M 2026-03
Vertex Pharmaceuticals USD 26.48B 841.4M 2026-03